中文摘要：

目的筛选问号钩端螺旋体（简称钩体）属特异性外膜蛋白OmpL1和LipL21有效T和B细胞联合抗原表位，为研制多抗原肽（multiple antigenic peptide，MAP）疫苗提供基础。方法采用生物信息学方法预测OmpL1和LipL21分子中T和B细胞联合抗原表位。采用PCR扩增候选联合抗原表位片段并分别构建其噬菌体展示系统。分别以rOmpL1或rLipL21、黄疸出血群赖株、钩体患者抗血清为一抗，采用Western blot检测各抗血清与目的表位的免疫反应性及其强度。结果通过抗原表位预测，选择了高分值的4个OmpL1和2个LipL21联合表位。经扩增获得了预期的各抗原表位片段，各目的表位序列均准确插入噬菌体PⅢ蛋白N端并有效表达。各抗血清均能识别上述6个联合表位。其中LipL21的97-112和176-184表位对任-抗血清均显示相似强度的杂交条带。综合4个OmpL1表位对3种抗血清的不同Western blot结果及其实际意义，杂交信号从强到弱依次为173-191、87-98、297-320和59-78表位。结论所研究的6个联合表位均分别为LipL21和OmpL1的有效抗原表位，其中LipL21的97-112、176-184和OmpL1的87-98、173-191表位可应用于钩体MAP疫苗研制。

英文摘要：

Objective To screen the efficient antigenic epitopes in genus-specific envelope proteins OmpL1 and LipL21 of Leptospira interrogans for further development of multiple antigenic peptide （MAP） vaccine. Methods Based on bioinformatic technique, the combined epitopes of T and B lymph-cytes in OmpL1 and LipL21 molecules were screened. Nucleotide fragments of each epitopes were amplified by PCR and then constructed their phage display systems. Using antisera against rOmpL1, rLipL21, L. interrogans serogroup Icterohaemorrhagiae strain Lai and leptospirosis patients＇ sera as the first antibodies, respectively, Western blot assays were performed to determine the immunoreactivity and reactive ability of the epitopes with different antisera. Results Four combined epitopes of OmpL1 and two combined epitopes of LipL21 were selected out by the predicting procedure. All the amplified epitope fragments were accurately inserted into the region at N end of phage PⅢ protein and successfully expressed. All of the antisera could recognize each of the epitopes. Based on the results of Western blot, the two LipL21 epitopes at 97-112 and 176-184 showed similar strong hybridization signals with any of the antisera, and the hybridization signals of four OmpL1 epitopes with the three antisera were 173-191, 87-98,297-320 and 59-78, from strong to weak. Conclusion The six combined epitopes in this study are efficiently antigenic. And the epitopes at positions 97-112 and 176-184 in LipL21 as well as the epitopes at position 87-98 and 173-191 in OmpL1 have a potential for developing leptospiral MAP vaccine.